Purpose-driven products.

continue

Filgrastim

Development Status: Clinical

Development Status:

Clinical

Reference Product Indications

  • Patients with cancer receiving myelosuppressive chemotherapy or induction and/or consolidation chemotherapy for AML
  • Patients with cancer undergoing bone marrow transplantation
  • Patients undergoing autologous peripheral blood progenitor cell collection and therapy
  • Patients with congenital neutropenia
  • Patients with cyclic or idiopathic neutropenia
  • Patients acutely exposed to myelosuppressive doses of radiation

Pegfilgrastim

Development Status: Clinical

Development Status:

Clinical

Reference Product Indications

  • Patients with cancer receiving myelosuppressive chemotherapy
  • Patients acutely exposed to myelosuppressive doses of radiation

Adalimumab

Development Status: Preclinical

Development Status:

Preclinical

Reference Product Indications

  • Rheumatoid arthritis
  • Juvenile idiopathic arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Adult Crohn's disease
  • Pediatric Crohn's disease
  • Ulcerative colitis
  • Plaque psoriasis
  • Hidradenitis suppurativa
  • Uveitis

Future products

Development Status: Preclinical

Development Status:

Preclinical

Additional pipeline products

In addition to our lead pipeline candidates, Adello has a number of products in early-stage development. These monoclonal antibodies (mAbs) treat a variety of diseases in a portfolio of therapeutic areas.

Learn more.

At Adello we are always open to interacting further with those who share our passion for biosimilars. For inquiries or partnership opportunities, please contact us. 

Contact